Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI319 in Advanced Malignant Tumors
NCT04708210Phase 1Unknown
- Sponsor
- Innovent Biologics
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IBI319 in cancer, sponsored by Innovent Biologics. Primary endpoints: Dose-Limiting Toxicity up to 2 years and Adverse Events up to 2 years. Status: unknown.
02
Drugs
IBI319
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04708210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04708210.